Andreas Pahl
CEO Heidelberg Pharma
Seminars
Wednesday 5th November 2025
From Bench to Breakthrough: The Evolution of Amanitin ADCs – Insights from HDP-101 Phase I/II & the Future of Payload Differentiation
5:00 pm
- Differentiation through payloads: showcasing amanitin payloads and stressing the need for new ADC payload MoAs
- Exploring Phase I/II dose expansion data of HDP-101 and evaluating clinical performance against conjugates with validated payloadsÂ
- Reflecting on the development journey of HDP-101 to understand the hurdles to overcome with bringing a novel ADC payload to the clinic
